Fisher Darrell R, Fahey Frederic H
*Versant Medical Physics and Radiation Safety, 229 Saint St., Richland, WA 99354 USA; †Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave., Boston, MA 02115 USA.
Health Phys. 2017 Aug;113(2):102-109. doi: 10.1097/HP.0000000000000674.
Effective dose was introduced by the ICRP for the single, over-arching purpose of setting limits for radiation protection. Effective dose is a derived quantity or mathematical construct and not a physical, measurable quantity. The formula for calculating effective dose to a reference model incorporates terms to account for all radiation types, organ and tissue radiosensitivities, population groups, and multiple biological endpoints. The properties and appropriate applications of effective dose are not well understood by many within and outside the health physics profession; no other quantity in radiation protection has been more confusing or misunderstood. According to ICRP Publication 103, effective dose is to be used for "prospective dose assessment for planning and optimization in radiological protection, and retrospective demonstration of compliance for regulatory purposes." In practice, effective dose has been applied incorrectly to predict cancer risk among exposed persons. The concept of effective dose applies generally to reference models only and not to individual subjects. While conceived to represent a measure of cancer risk or heritable detrimental effects, effective dose is not predictive of future cancer risk. The formula for calculating effective dose incorporates committee-selected weighting factors for radiation quality and organ sensitivity; however, the organ weighting factors are averaged across all ages and both genders and thus do not apply to any specific individual or radiosensitive subpopulations such as children and young women. Further, it is not appropriate to apply effective dose to individual medical patients because patient-specific parameters may vary substantially from the assumptions used in generalized models. Also, effective dose is not applicable to therapeutic uses of radiation, as its mathematical underpinnings pertain only to observed late (stochastic) effects of radiation exposure and do not account for short-term adverse tissue reactions. The weighting factors incorporate substantial uncertainties, and linearity of the dose-response function at low dose is uncertain and highly disputed. Since effective dose is not predictive of future cancer incidence, it follows that effective dose should never be used to estimate future cancer risk from specific sources of radiation exposure. Instead, individual assessments of potential detriment should only be based on organ or tissue radiation absorbed dose, together with best scientific understanding of the corresponding dose-response relationships.
国际放射防护委员会(ICRP)引入有效剂量是为了实现设定辐射防护限值这一单一的总体目标。有效剂量是一个导出量或数学概念,而非物理上可测量的量。计算参考模型有效剂量的公式包含了用于考虑所有辐射类型、器官和组织放射敏感性、人群组以及多个生物学终点的各项。健康物理学领域内外的许多人对有效剂量的特性和恰当应用了解不足;在辐射防护领域,没有其他量比它更令人困惑或误解。根据ICRP第103号出版物,有效剂量应用于“放射防护规划与优化中的前瞻性剂量评估,以及用于监管目的的回顾性合规证明”。在实践中,有效剂量被错误地用于预测受照人群的癌症风险。有效剂量的概念通常仅适用于参考模型,不适用于个体。虽然有效剂量被设想为代表癌症风险或遗传有害效应的一种度量,但它并不能预测未来的癌症风险。计算有效剂量的公式纳入了委员会选定的辐射品质和器官敏感性加权因子;然而,器官加权因子是所有年龄和性别的平均值,因此不适用于任何特定个体或如儿童和年轻女性等放射敏感亚人群。此外,将有效剂量应用于个体医疗患者并不合适,因为患者特定参数可能与通用模型中使用的假设存在很大差异。而且,有效剂量不适用于辐射的治疗用途,因为其数学基础仅涉及观察到的辐射暴露晚期(随机)效应,并未考虑短期不良组织反应。加权因子包含大量不确定性因素,低剂量下剂量 - 反应函数的线性也不确定且备受争议。由于有效剂量不能预测未来癌症发病率,因此有效剂量绝不应被用于估计特定辐射暴露源导致的未来癌症风险。相反,对潜在损害的个体评估应仅基于器官或组织的辐射吸收剂量,以及对相应剂量 - 反应关系的最佳科学理解。